Galapagos NV (NASDAQ:GLPG) has earned a consensus rating of “Buy” from the eight brokerages that are presently covering the stock. Three investment analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is €66.25 ($73.61).
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Galapagos NV from a “buy” rating to a “hold” rating in a report on Monday. Janney Montgomery Scott initiated coverage on shares of Galapagos NV in a report on Tuesday, August 30th. They set a “buy” rating and a $64.00 price objective on the stock. Finally, Credit Suisse Group AG reiterated a “hold” rating and set a $48.00 price objective on shares of Galapagos NV in a report on Friday, June 17th.
A number of hedge funds and other institutional investors have recently bought and sold shares of GLPG. Fiera Capital Corp acquired a new position in Galapagos NV during the second quarter valued at approximately $302,000. Citadel Advisors LLC acquired a new position in Galapagos NV during the second quarter valued at approximately $347,000. A.R.T. Advisors LLC acquired a new position in Galapagos NV during the first quarter valued at approximately $547,000. Landscape Capital Management L.L.C. raised its position in Galapagos NV by 114.7% in the first quarter. Landscape Capital Management L.L.C. now owns 17,389 shares of the company’s stock valued at $727,000 after buying an additional 9,288 shares during the last quarter. Finally, P.A.W. Capital Corp acquired a new position in Galapagos NV during the second quarter valued at approximately $1,109,000.
Galapagos NV (NASDAQ:GLPG) traded down 1.29% on Tuesday, reaching $64.16. 34,639 shares of the company’s stock traded hands. Galapagos NV has a 52 week low of $37.03 and a 52 week high of $73.37. The firm’s market capitalization is $2.96 billion. The stock has a 50-day moving average of $58.65 and a 200 day moving average of $52.67.
About Galapagos NV
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.